A detailed history of Tower Research Capital LLC (Trc) transactions in Rallybio Corp stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 3,460 shares of RLYB stock, worth $3,287. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,460
Previous 13,179 73.75%
Holding current value
$3,287
Previous $17,000 76.47%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.09 - $1.45 $10,593 - $14,092
-9,719 Reduced 73.75%
3,460 $4,000
Q2 2024

Aug 13, 2024

BUY
$1.34 - $2.98 $6,780 - $15,078
5,060 Added 62.32%
13,179 $17,000
Q1 2024

May 15, 2024

BUY
$1.25 - $2.4 $5,512 - $10,584
4,410 Added 118.9%
8,119 $15,000
Q4 2023

Feb 13, 2024

BUY
$1.91 - $4.39 $1,955 - $4,495
1,024 Added 38.14%
3,709 $8,000
Q3 2023

Nov 14, 2023

BUY
$3.37 - $6.16 $3,848 - $7,034
1,142 Added 74.01%
2,685 $9,000
Q2 2023

Aug 14, 2023

SELL
$4.31 - $8.89 $2,202 - $4,542
-511 Reduced 24.88%
1,543 $8,000
Q1 2023

May 09, 2023

BUY
$4.37 - $8.75 $4,335 - $8,680
992 Added 93.41%
2,054 $12,000
Q4 2022

Feb 10, 2023

SELL
$4.67 - $14.86 $9,863 - $31,384
-2,112 Reduced 66.54%
1,062 $7,000
Q3 2022

Nov 10, 2022

BUY
$7.54 - $14.56 $9,289 - $17,937
1,232 Added 63.44%
3,174 $46,000
Q2 2022

Aug 15, 2022

BUY
$6.26 - $13.65 $3,943 - $8,599
630 Added 48.02%
1,942 $15,000
Q1 2022

May 12, 2022

SELL
$6.91 - $15.04 $9,128 - $19,867
-1,321 Reduced 50.17%
1,312 $9,000
Q4 2021

Feb 14, 2022

BUY
$9.3 - $19.91 $20,097 - $43,025
2,161 Added 457.84%
2,633 $25,000
Q3 2021

Nov 15, 2021

BUY
$10.83 - $23.4 $5,111 - $11,044
472 New
472 $8,000

Others Institutions Holding RLYB

About Rallybio Corp


  • Ticker RLYB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,132,000
  • Market Cap $30.5M
  • Description
  • Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of feta...
More about RLYB
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.